Reagila is indicated for the treatment of schizophrenia in adult patients¹ .

Patients with different symptoms and in different stages of their disease will have different needs. This means that doses of Reagila, switching strategies, and co-medications may differ based on the individual patient’s status. Therefore, making a thorough evaluation of the patient’s current state and current medications might be a useful way to start a treatment plan using Reagila.

Based on efficacy and tolerability in clinical studies, the approved dose range of REAGILA for the treatment of schizophrenia in adult patients is 1.5-6 mg/d¹. REAGILA comes in 4 different dose strengths (1.5 mg, 3 mg, 4.5 mg, and 6 mg) and all doses are effective in treating schizophrenia¹.

The recommended starting dose of REAGILA is 1.5 mg once daily¹. Thereafter the dose can be increased slowly in 1.5 mg increments to a maximum dose of 6 mg/d, if needed¹.

REAGILA is for oral use and it is taken once daily with or without food¹. REAGILA should be taken at the same time every day – however, it is not restricted to either mornings or evenings¹. Patients can take REAGILA when it’s most convenient for them, but they should be aware that REAGILA has activating qualities rather than sedating ones², which could be a potential consideration in regard to when to take it.

REAGILA has 2 active metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR). Total cariprazine (the parent drug, DCAR, and DDCAR) reaches steady state in 3 to 4 weeks; 90% of steady state is achieved within 1 week for cariprazine and DCAR, and within 4 weeks for DDCAR¹.

Reference: Adapted from Nakamura, T. et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des. Devel. Ther. 10, 327–338 (2016)³

For the management of patients treated with REAGILA, the effective half-life is more relevant than the terminal half-life. The effective (functional) half-life is ~ 2 days for cariprazine and DCAR, 8 days for DDCAR, and ~1 week for total cariprazine. The plasma concentration of total cariprazine will gradually decline following dose discontinuation or interruption, and will decrease by 50% in ~1 week and by >90% in ~3 weeks¹.